Table 2.
Cytostatic and anti-HIV-1 and -HIV-2 activities of eremomycin aglycon and teicoplanin aglycon derivatives (Fig. 4, Fig. 5) against different HIV-1 and HIV-2 strains and in different cell lines (Anon, 2002)
| Compound | IC50a |
ED50b |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| L1210 | MOLT-4/C8 | CEM | C8166 | MOLT-4/8 | CEM/0 |
|||||
| HIV-1c (III B) | HIV-1c (HE) | HIV-1c (IIIB) | HIV-1c (HE) | HIV-2c (EHO) | HIV-1c (MN) | HIV-2 (RF)c | ||||
| 15 | 250 | >500 | >500 | ND | 22 | 5.5 | 40 | 50 | 20 | 16 |
| 16 | 12 | 19 | 9.4 | 9.0 | 7.5 | 7.5 | 17 | 11 | 12 | 8.5 |
| 17 | 43 | 136 | 179 | 9.5 | 9.0 | 6.0 | 12 | 15 | 13 | 9.5 |
| 18 | 23 | 35 | 90 | ≥5 | 4.5 | 2.8 | 5.5 | 11 | 7.0 | 3.7 |
| 19 | 51 | 65 | 74 | 6.6 | 3.7 | 2.8 | 9.5 | 6.8 | 6.5 | 3.7 |
a
Inhibitory concentration, or compound concentration required to inhibit cell proliferation by 50%.
b
Effective concentration or concentration required to protect C8166, MOLT-4/C8 or CEM cells against the cytopathicity of the different HIV strains by 50%.
c
Different types of the HIV strains.